Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | PARP1 | P09874 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | TYMP | P19971 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7029630 | 0.87 | KDM4E (0.53) | KDM4EPARP1CA12CA9PDE3A | |
| SCHEMBL7025839 | 0.86 | CA12 (0.45) | KDM4EPARP1CA12CA9TYMP | |
| SCHEMBL9761081 | 0.81 | KDM4E (0.46) | KDM4EPARP1CA12CA9TYMP | |
| SCHEMBL29693067 | 0.81 | MEN1 (0.53) | KDM4EFEN1ALDH1A1KMT2AMEN1 | |
| SCHEMBL7030552 | 0.79 | PARP1 (0.44) | KDM4EPARP1CA12CA9TYMP | |
| SCHEMBL7034143 | 0.78 | CA12 (0.50) | KDM4EPARP1CA12CA9TYMP | |
| SCHEMBL20942693 | 0.78 | GAA (0.66) | KDM4EPARP1CA12CA9TYMP | |
| SCHEMBL2056368 | 0.78 | ALDH1A1 (0.50) | KDM4EPARP1CA12CA9ALDH1A1 | |
| SCHEMBL7028337 | 0.78 | CA12 (0.50) | KDM4EPARP1CA12CA9TYMP | |
| SCHEMBL17274741 | 0.76 | AHR (0.55) | KDM4EFEN1ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087193-A1 | TRIAZOLOQUINAZOLINONE SYNTHESIS | GABATHER AB (SE) | 2021-03-25 | — | — | US | disclosed |
| EP-0878468-B1 | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| EP-0775697-B1 | Process for producing 1-substituted tetrahydroquinazolindionen | SUMITOMO CHEMICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-5994542-A | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0878468-A1 | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-11-18 | — | — | EP | disclosed |
| US-5756738-A | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0775697-A1 | Process for producing 1-substituted tetrahydroquinazolindionen | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087193-A1 | TRIAZOLOQUINAZOLINONE SYNTHESIS | CYP3A5, CYP2C19, CYP3A7 | KDM4E 459/4885PARP1 548/4885CA12 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.